Rhythm Pharmaceuticals (RYTM) Total Debt (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Total Debt data on file, last reported at $108.5 million in Q1 2026.

• On a quarterly basis, Total Debt fell 0.96% year-over-year to $108.5 million in Q1 2026; TTM through Mar 2026 was $108.5 million, a 0.96% decrease from a year earlier, with the FY2025 full-year figure at $108.2 million, down 1.48% from the prior year.
• Total Debt for Q1 2026 stood at $108.5 million, roughly flat from $108.2 million in the prior quarter.
• Over the last five years, Total Debt for RYTM reached as high as $109.8 million in Q4 2024 and fell as low as $34.3 million in Q2 2022.
• Historically, Total Debt has averaged $96.5 million across 5 years, with a median of $108.5 million in 2026.
• Across the five-year window, Total Debt gained 3.45% in 2024 and slipped 1.48% in 2025, its largest moves.
• Year by year, Total Debt stood at $73.0 million in 2022, then jumped by 45.48% to $106.1 million in 2023, then rose by 3.45% to $109.8 million in 2024, then fell by 1.48% to $108.2 million in 2025, then increased by 0.27% to $108.5 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $108.5 million in Q1 2026, $108.2 million in Q4 2025, and $109.0 million in Q3 2025.